DEFENDANT TURTLE WAX, INC.'S EXHIBIT B



Deposition of: **Robert F. Herrick , Sc.D., CIH, FAIHA**

November 6, 2019

In the Matter of:

Benzene - Rhyne, Bruce v. U.S. Steel

Veritext Legal Solutions

888.777.6690 | cs-midatlantic@veritext.com | 215-241-1000

- 1 Ο. Okay. Does the report contain all of your opinions in this matter? 2 3 Yes, it does. Yeah. Α. Did anyone else participate in the 4 Ο. 5 preparation of the report? Well, aside from the -- the person, you 6 7 know, the -- the staff I mentioned at EH&E, who contributed to, you know, helping me put together 8 the work histories, but no one other than that. 10 Ο. Okay. Obviously the report refers to some modeling you did; is that correct? 11 12 Α. Right. Yes. 13 Q. Or modeling that was done. 14 Did you do the modeling yourself? Yes, I did. 15 Α. So you sat in front of the computer and 16 Ο. 17 actually did the model? 18 I did, yes. Α. 19 Okay. And you picked all of the -- I mean, we're going to get into this later -- but 20 21 obviously you relied -- at least in part -- on the
 - A. That's correct.

ART model?

22

23

24

25

Q. Okay. And the ART model contains -- MR. DuPONT: Objection to form.

Q. Okay. Okay.

2

3

4

5

6

7

8

9

10

11

12

13

16

17

18

19

2.0

21

22

23

24

25

Did you ever speak to anyone else in this case, other than perhaps coworkers at EH&E and Mr. DuPont?

Have you talked to anyone else?

- A. No, I haven't.
- Q. You -- you are not a medical doctor; is that right?
 - A. That's correct, yeah.
 - Q. You're not a toxicologist.
 - A. No, I'm not.
 - Q. You're not an epidemiologist.
- A. I'm not.
- Q. Your report does not contain an opinion on general medical causation.
 - A. It does not.
 - Q. Or specific medical causation.
 - A. Neither, no.
 - Q. And your report does not contain an opinion on warnings.
 - A. No, it doesn't.

MR. FISHKIN: I'll mark -- I have a -- I'm going to mark as Herrick 3 what purports to be your CV with a date of August of 2019.

(Exhibit Herrick 3, Robert F. Herrick

L	manufactured	by	Magnuflux	Corporation?
2.	MR.	Dul	PONT: Forr	n .

- A. No, I don't -- oh, well, sure -- sure I do, 'cause here it is. It's -- I mean, it does mention Magnuflux in the Approved Chemical List.

 So yeah, I do see that.
- Q. Do you understand that Magnaflux Corporation is not a named defendant in the case?
 - A. Oh, no, I guess they're not.
- Q. Did Mr. Rhyne have benzene exposures from daily living every day of his life before he was diagnosed with AML -- separate and apart from any exposures that he had to benzene from the products that you talk about in Tables 3 and 4?

MR. DuPONT: Form.

- A. Okay. So you're referring to, say, nonoccupational exposures?
- Q. Well, I think your report talks about nonoccupational exposure to certain products.

So I'm talking about did he have -- or I'm asking about whether he had benzene exposures from daily living, separate and apart from any benzene to which he was exposed from the products on Tables 3 and 4?

MR. DuPONT: Form.

25

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

2.3

2 3

A. Yeah, I mean, he probably had the same kind of exposures that, you know, most of us have. There's benzene levels in ambient air -- varied, you know, quite a lot, depending on where you live.

He -- I don't remember if this came up, but he very likely pumped his own gas at the gas station and filled his car. So, you know, he had that source.

He wasn't a smoker, so, you know, I think that's -- that's, you know, sort of, off the table. That's always, you know, something to consider.

And I don't know that he, you know, I don't remember from the record if he lived with anyone who smoked. I just don't remember that part.

- Q. Did you in your report estimate his daily exposure to benzene, separate and apart from what you believe he was exposed to from the products in this case?
 - A. No, I didn't.
- Q. Did you in your report calculate his cumulative exposure to benzene from daily living in the nearly 60 years before he was diagnosed with AML, separate and apart from benzene to which he was exposed to the products that you list in Tables

off the record or not, but my name's Virginia
Wooten, and I represent Turtle Wax in this matter.
I just have a few questions for you, and they're
mainly going to be a product called Marvel Mystery
Oil.

A. Oh, sure.

2.0

2.2

- Q. And just to start, all your opinions regarding Rhyne's exposure to any benzene and Marvel Mystery Oil are contained in your report; correct?
 - A. That's right, yeah.
- Q. And if you look at Table 3 on page 39 in your report, and you go down to where Marvel Mystery Oil is listed, and under the "Daily Exposure Midpoint," it says, "Not determined"; is that correct?
 - A. That's correct, yeah.
 - Q. And why is that?
- A. Well, it was really my view of the way he was using that particular product, and my recollection was -- you know, and he -- he talked about this in his deposition -- that he was adding that liquid to these cylinders, I think I would call them; they were reservoirs that were on the vibrators that he was doing this maintenance work

on. And so, as he described what he did, it seemed to me that the opportunity for there to be substantial vapor exposure was really very minor.

- Q. And, then, in Table 4 on page 43, if you look down at where Marvel Mystery Oil is listed, once again, under the "Cumulative Exposure Midpoint" it says, "Not determined." Is that a similar reason as to why that's not determined in that table as well?
- A. Right, because I -- what I, you know, tried to do was -- was talk about -- in -- in the narrative that precedes this -- what was in the record about the composition of the Marvel Mystery Oil; and I, you know, recognized, you know, the -- the ingredients, you know, the petroleum-based ingredients as being things that, over time, you know, could have had benzene as one of the ingredients -- one of the components. But what was really, you know, sort of, leading me to this "Not determined" classification was the way he was using it.
- Q. So were you unable to, I guess, get a cumulative exposure based upon the way he was using it?
 - A. That was really what was -- what was

1 driving it, yeah.

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24

25

- Q. Okay. So there's no -- you did not calculate any cumulative exposure for Marvel Mystery Oil in this matter?
 - A. I didn't.
- Q. Okay. And if you turn to page 44 in your "Conclusions" page, you would agree that there's no conclusion regarding Marvel Mystery Oil listed on that page.
- A. Let me just double-check. (Witness reviews document.) No, there is not.
- Q. Okay. And my guess is there's not going to be a model report attached in your appendix specifically for Marvel Mystery Oil in your report.
- A. No, I didn't do any calculations or develop any modeling for that.
- Q. And if we go back to -- I believe it's page 29 of your report, you discuss Marvel Mystery Oil on page 29, and if you look at the second full paragraph on page 29, it, kind of, discusses Mr. Rhyne's use of Marvel Mystery Oil.

Is your understanding of how Mr. Rhyne used the Marvel Mystery Oil from his deposition?

- A. It is, yeah.
- Q. Is there any other source you are using to

Veritext Legal Solutions

determine how he would use Marvel Mystery Oil?

the work process was conducted.

A. No, just his description of the -- the way

_

Q. Okay. If you look at that last full paragraph on page 29, the first sentence, and I'll just read it: "As of 1985 Marvel Mystery Oil is reported to contain mineral spirits, 30 percent, and naphthenic base oil distillate, 67 percent."

- A. Right.
- Q. And where are you getting that from?
- A. I'd have to go back into my files. I think I -- it's either from a safety data sheet or from some, you know, possibly correspondence that I have in the record about the composition of this product.
- Q. Sure. And I'll -- I'll represent to you we received a Dropbox earlier today, and it had two Material Safety Data Sheets for Marvel Mystery Oil contained in it.

Do you know if you used two separate data sheets for Marvel Mystery Oil?

A. I did, and -- and it is, kind of, coming back to me now. As I recall, the -- the first one, the one from 1985 really was pretty sparse. You know, there wasn't really very much information

contained in that, other than what I've presented here.

And, then, the one from 1995 and, then, these others that I mentioned for, you know, later dates had a lot more detail.

- Q. Do you know if you pulled those Material Safety Data Sheets, or if you were provided those sheets?
 - A. I think they were provided.
- Q. And, then, same thing: Paragraph 3 on page 29, in that second sentence, is that coming from a Material Safety Data Sheet as well?
 - A. It is, yeah.
- Q. Same thing with the -- the next sentence. Would that be from your review of safety data sheets?
 - A. Right, those are.
- Q. Okay. And, then, there's the next sentence: "In the time period when Mr. Rhyne used this product at Catawba --" from 1986 to 1998 "-- the benzene contents of the petroleum derived solvents reportedly ranged from 100 to 2,000 --" parts per million.

And where is that coming from?

A. Oh, what I was reflecting there -- and I

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

think, you know, probably the -- the underlying source there is that review article that Williams prepared --

- Q. Uh-huh.
- A. -- because in her supplementary tables she has a variety of products over time.
 - O. Uh-huh.
- A. And so among these mineral spirits or petroleum distillate products, that was the range that she reported going over this, you know, 20-year time period.
- Q. Okay. And, then, it looks like the last sentence says when you determined that the range of Rhyne's benzene exposures from Marvel Mystery Oil "-- to be .01 to 1 parts per million with a midrange value of .5 parts per million for the duration of each use," and how did you come up with that calculation?
- A. Yeah. That actually would have been what I -- you know, again, that's -- that's based on the range of exposures that Williams had reported for the materials that ranged from 100 to 2,000 parts per million.

So, again, that -- and that's from the supplementary table No. 1 in her report.

2.0

2

Ο. Okay.

3

5

6 7

8

9 10

11

12 13

14

15

16 17

18

2.0

19

21 22

2.3 24

25

But, you know, since I later decided that I really just didn't feel comfortable trying to determine the exposure level, I really should have taken that last sentence out.

- So sitting here today you believe you should have taken the last sentence out of paragraph 3 on page 29 out of the report?
- Well, reflecting on, you know, as I really tried to think about, you know, both the potential content of benzene in the material, but also what I concluded or inferred about the way he was using it, I really didn't feel that there was a substantial opportunity for him to have exposure.

So that that's why I gave it this category as "Not determined."

- Q. As far as any benzene that would be contained in Marvel Mystery Oil, would that be coming from the mineral spirits only?
 - Well, in some --Α.

MR. DuPONT: Objection. Form.

I'm sorry. THE WITNESS:

Α. No, some of these, you know, ingredients that are listed, say, like, in -- in 1985, you know, we have the "mineral oil petroleum distillate solvent dewax severe," I mean, they're, you know,
"heavy naphthenic petroleum lubrication oil," you
know, so there's a range of, I mean, ingredients
there that could potentially contain benzene.

- Q. And can you just go over which ingredients you believe --
- A. Well, I think, you know, you clearly could have had from -- from the petroleum distillate solvent refined the heavy naphthenic petroleum lube oil, the Stoddard Solvent mineral spirits. I mean, I think those three would be candidates.
- Q. And you did not perform any product testing on Marvel Mystery Oil; is that correct?
 - A. No, I haven't.
- Q. And you haven't provided any opinion regarding dermal exposure to Marvel Mystery Oil.

MR. DuPONT: Objection. Form.

A. No.

MS. WOOTEN: Doctor Herrick, I believe that is all the questions I have for you right now. Thank you.

MR. DuPONT: It's been about an hour. Take a quick break.

(Recess was taken.)

EXAMINATION

2425

1

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23